Abstracting and indexing is the process by which a bibliographic database systematically catalogs a journal’s articles, capturing standardized metadata such as titles, authors, affiliations, abstracts, keywords and references, and making that metadata searchable across a global platform. The practical consequence for researchers is discoverability. An article that appears only on an individual journal website exists in a kind of bibliographic isolation, reachable mainly by readers who already know the journal. Once a journal is indexed in the Science Citation Index Expanded, its content becomes discoverable through Web of Science search tools, its citation links become traceable through the database’s cited-reference searching, and its cumulative performance becomes visible to the librarians, funders and evaluation committees who rely on these databases when they assess journals and institutions. In an era when most literature discovery begins with a database query rather than a browse of a journal’s table of contents, indexing status is a structural determinant of a paper’s audience.

The Science Citation Index Expanded is the multidisciplinary extension of the original Science Citation Index, the citation database created by Eugene Garfield in the 1960s and now maintained as part of the Web of Science Core Collection. The index covers thousands of journals across the natural sciences, applied sciences and medicine, and its selection process is deliberately selective. Editors evaluating a journal for inclusion consider a range of quality signals: the rigor and consistency of peer review, the international diversity of the editorial board and authorship, the regularity of publication, the ethical publishing standards in place, and the citation behavior of the journal’s published content. Journals are re-evaluated continuously, and inclusion is not permanent, which means that a journal’s presence in the index is itself an ongoing signal that its editorial standards continue to meet the database’s criteria.

The impact factor reported alongside the indexing record is the metric most closely watched by authors deciding where to submit their work. Calculated annually by Clarivate from the citation data in the Web of Science, the two-year impact factor for a given year is the ratio of citations received in that year to the number of substantive items, typically articles and reviews, published in the journal during the two preceding years. A 2022 impact factor of 5.5 therefore reflects citations accumulated in 2022 by papers published in 2020 and 2021, divided by the count of those papers. For a journal that entered the index in 2021, this figure arrives early in its indexed life, since new journals typically need a settling period before their citation patterns stabilize. The value of 5.5 indicates that, on average, each citable item published in the journal during the measurement window drew more than five citations in the following year, a level of citation intensity that corresponds to a strong, internationally visible research venue in the pharmaceutical field.

Quartile placement translates that raw number into context. Journals in a Web of Science category are ranked by impact factor and divided into four groups, with the first quartile, Q1, containing the top 25 percent. The Journal of Pharmaceutical Investigation’s position at 48 out of 278 journals in Pharmacology and Pharmacy places it firmly within that top band, ahead of roughly four-fifths of the journals in its category. The rank matters because impact factors are meaningful only in comparison. A value of 5.5 might be modest in a field with extremely high citation rates and exceptional in a field where citation density is low; the quartile ranking situates the journal relative to the actual distribution of its peers in pharmacology and pharmacy. Authors evaluating potential outlets, and readers skimming reference lists for authoritative sources, use these rankings as a fast heuristic for gauging where a journal stands within its discipline.

The downstream effects of this status are practical for the research community. Authors gain a publication venue whose indexed metrics can be cited in grant applications, promotion dossiers and funder reports, where journal quality is often assessed through Web of Science-based indicators. Institutions benefit because their researchers’ publications contribute to institutional citation profiles and to the global university rankings that draw heavily on Web of Science data. Readers benefit from the cited-reference network that the index builds, allowing them to trace the lineage of a finding backward through earlier work and forward through later citations. Librarians use the indexing record and the impact factor when making subscription decisions, which in turn supports the journal’s financial sustainability. In this way, a single indexing milestone ripples outward through nearly every stakeholder in the scientific communication system.

The pharmaceutical sciences present a particularly demanding environment for journal metrics. The field spans drug discovery, formulation science, pharmacokinetics, drug delivery systems, clinical pharmacology and regulatory science, and its publication landscape is crowded with long-established titles backed by major societies and commercial publishers. Citation behavior in the field is shaped by translational urgency: work on delivery platforms, biologics and therapeutic development often draws attention from both basic researchers and clinical communities, which can drive citation counts upward for journals positioned at those intersections. A journal focused on pharmaceutical investigation sits naturally in that translational zone, and the first-quartile ranking suggests that its published research is being picked up across both the pharmaceutical technology and the pharmacology communities that make up its readership.

At the same time, the announcement is a fitting occasion to recall the limits of the metrics involved. The research community has increasingly emphasized responsible use of quantitative indicators. The San Francisco Declaration on Research Assessment, signed by thousands of journals, funders and institutions, urges that impact factors not be used as a surrogate for the quality of individual papers or the merit of individual researchers, since citation counts are influenced by article type, review articles inflate averages, and two-year windows capture only a slice of a paper’s scholarly lifetime. Altitude within a quartile shifts year to year as citation patterns fluctuate, and a journal’s impact factor is a property of the journal, not a guarantee about any single article it publishes. The appropriate reading of the 2022 record is therefore as a signal of the journal’s overall standing and editorial health, not as a per-article quality certificate.

For the broader community of pharmaceutical researchers, the development adds one more indexed, first-quartile outlet to a field where the demand for visible, credible publication venues remains intense. Inclusion in the Science Citation Index Expanded from 2021 onward means that the journal’s recent volumes are being woven into the global citation fabric that underlies literature search, systematic review, bibliometric analysis and research evaluation. Its 2022 impact factor of 5.5 and its Q1 position at 48 of 278 journals in Pharmacology and Pharmacy provide a quantified snapshot of that integration. Whether the journal sustains and improves those numbers will depend on the same fundamentals that determine any journal’s trajectory: the quality and relevance of the research it attracts, the rigor of its peer review, and its continued adherence to the editorial standards that earned it entry into one of scholarly publishing’s most closely watched databases.

Subject of Research: Indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its 2022 impact factor of 5.5 in pharmacology and pharmacy.

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: abstracting and indexing, Science Citation Index Expanded, impact factor, Journal of Pharmaceutical Investigation, pharmacology, pharmacy, Web of Science, quartile ranking, scholarly publishing, pharmaceutical sciences, journal metrics, research visibility

Abstracting and indexing, often abbreviated as A&I, is the process by which bibliographic databases catalog scholarly articles, capturing their titles, authors, abstracts, keywords and citations in structured records that can be searched, sorted and analyzed at scale. For researchers, these databases are the primary discovery tools of modern science: a paper that is not indexed in the major services is effectively invisible to most of the global research community, no matter how rigorous its methods or how significant its findings. For journals, inclusion in prestigious indexes is both a badge of quality and a practical necessity, because libraries, funders and tenure committees routinely evaluate publications based on where they are indexed and what citation metrics those indexes generate.

The Journal of Pharmaceutical Investigation has been abstracted and indexed in the Science Citation Index Expanded, commonly known as SciSearch, since 2021. The Science Citation Index Expanded is maintained by Clarivate as part of the Web of Science platform, one of the most authoritative citation databases in the world. It traces its lineage to the original Science Citation Index created by Eugene Garfield in the 1960s, a pioneering effort to map the flow of ideas through the scientific literature by tracking which papers cite which. That citation network remains the foundation of modern bibliometrics, and inclusion in the expanded index signals that a journal has passed a rigorous editorial evaluation covering publishing standards, editorial content, international diversity and citation behavior.

Once a journal is indexed in the Science Citation Index Expanded, it becomes eligible for the Journal Impact Factor, the single most widely cited metric in scholarly publishing. The impact factor is calculated by dividing the number of citations received in a given year by items published in the journal during the two preceding years. A journal’s 2022 impact factor of 5.5 therefore means that, on average, articles published in 2020 and 2021 were cited 5.5 times each during 2022. While the metric has well-documented limitations, it remains a shorthand that researchers, institutions and publishers watch closely, and movement in the rankings can shape manuscript submission patterns, editorial strategies and even national research assessment frameworks.

A ranking of 48 out of 278 journals places the Journal of Pharmaceutical Investigation in the first quartile, or Q1, of the Pharmacology and Pharmacy category, meaning it sits among the top 25 percent of titles in its field. Quartile rankings are derived by ordering journals within a category by impact factor and dividing them into four equal bands. Q1 status is particularly meaningful in pharmacology, one of the most competitive categories in the Web of Science, where established titles with decades of history and enormous submission volumes compete for citation attention. For a journal to reach and hold a Q1 position, its published work must not only meet high editorial standards but also resonate with a broad community of researchers who choose to cite it in their own studies.

The journal’s subject matter helps explain that resonance. Pharmaceutical investigation encompasses the entire lifecycle of a drug, from early discovery and formulation science through pharmacokinetics, pharmacodynamics, clinical evaluation, manufacturing quality and post-marketing surveillance. Research in this space is inherently translational, connecting laboratory findings to therapeutic outcomes, and it draws citations from a wide range of adjacent disciplines, including biotechnology, nanomedicine, regulatory affairs and clinical pharmacy. Journals that publish work spanning this breadth tend to accumulate citations from many communities, which strengthens their bibliometric performance and, in a self-reinforcing loop, attracts further high-quality submissions from authors seeking visibility.

The timing of the journal’s SciSearch inclusion in 2021 and its subsequent impact factor performance illustrates a broader dynamic in scholarly publishing. New or newly indexed journals typically need two full publication cycles before their first official impact factor can be calculated, because the metric depends on a two-year citation window. The years immediately following indexing are therefore critical: editors work to commission review articles, which are disproportionately cited, and to attract original research from prominent groups, knowing that early citation performance will set the trajectory of the journal’s metrics for years to come. Achieving a 5.5 impact factor within a short period of entering the index suggests that the journal’s editorial strategy and its community of contributors have aligned effectively with the citation patterns of contemporary pharmaceutical research.

Behind the headline numbers lies an elaborate ecosystem of data infrastructure. When an article is published, its metadata are transmitted to indexing services, where they are normalized against standards for author names, affiliations, funding information and references. Citation links are then resolved and aggregated, feeding not only the impact factor but also a family of related indicators, including the five-year impact factor, the immediacy index, the cited half-life and the eigenfactor, each of which captures a different dimension of a journal’s scholarly footprint. Databases also power literature search engines, reference managers and systematic review workflows, meaning that indexing quality directly affects how efficiently science itself proceeds. Errors or gaps in indexing can delay discoveries, skew bibliometric analyses and misrepresent the provenance of ideas.

For the pharmaceutical sciences specifically, robust indexing carries practical stakes beyond prestige. Systematic reviews and meta-analyses, which underpin clinical guidelines and regulatory decisions, depend on comprehensive database coverage to identify all relevant evidence. Pharmacovigilance researchers tracking adverse events, formulation scientists surveying delivery technologies and health economists assessing drug value all rely on indexed literature to build complete pictures of the evidence base. A journal’s presence in the Science Citation Index Expanded therefore contributes to the reliability of the evidence synthesis on which drug safety and efficacy decisions ultimately rest, a responsibility that extends well beyond the publishing world into patient care.

The Journal of Pharmaceutical Investigation’s Q1 standing in 2022 is a snapshot of a competitive and rapidly evolving field, and maintaining that position will require continued editorial rigor as publishing itself changes. Preprint servers, open access mandates, alternative metrics and new assessment frameworks such as the Declaration on Research Assessment are reshaping how scholarly value is measured, and citation-based indicators are increasingly scrutinized for the ways they can be gamed or misapplied. Yet for now, the combination of SciSearch indexing and a 5.5 impact factor confirms the journal’s place among the leading venues for pharmaceutical research, offering authors a platform with global discoverability and offering readers a curated window into the science that moves molecules from the bench to the bedside.

Subject of Research: The indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its 2022 impact factor and Q1 ranking in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, impact factor, abstracting and indexing, Science Citation Index Expanded, Web of Science, pharmacology, pharmacy, Q1 journal, citation metrics, pharmaceutical sciences, bibliometrics, Clarivate

Abstracting and indexing is the infrastructure that underpins the modern scientific record. When a journal is accepted into a major citation index, its articles become discoverable through the databases that scientists, clinicians, and institutions rely on every day to survey the literature. The Science Citation Index Expanded, maintained within the Web of Science platform, is one of the most selective and influential of these databases. Inclusion signals that a journal has passed rigorous editorial evaluation covering publishing standards, peer-review integrity, international editorial breadth, and citation behavior. For a journal to be abstracted and indexed in SciSearch from 2021 onward means that every article it publishes is now woven into the global web of citation data that powers literature searches, systematic reviews, bibliometric analyses, and institutional assessments.

The consequences of that inclusion ripple outward quickly. A paper on a novel nanoparticle formulation or a new approach to oral drug absorption that might once have been seen primarily by the journal’s existing readership can now surface in the reference lists, alerts, and search results of researchers on every continent. Citations accumulate, and those citations feed directly into the journal’s Impact Factor, the most scrutinized single number in scholarly publishing. The 2022 Impact Factor of 5.5 for the Journal of Pharmaceutical Investigation reflects the average number of times articles published in the preceding two years were cited during 2022. Crossing the threshold into double-digit percentile territory in a crowded category is a meaningful achievement that reflects both the quality of the work the journal publishes and the engagement of the community that reads it.

The ranking attached to that Impact Factor deserves particular attention. The Journal of Pharmaceutical Investigation’s position of 48 out of 278 journals in the Pharmacology and Pharmacy category places it in the Q1 band, the top quartile of its discipline. Quartile rankings divide a category’s journals into four groups by citation performance, and Q1 status is frequently used by funding agencies, hiring committees, and universities as shorthand for excellence. In a field as broad and competitive as pharmacology and pharmacy, which spans everything from medicinal chemistry and pharmacokinetics to clinical pharmacy practice and health economics, occupying the top quartile requires a journal to be cited at rates that exceed roughly three-quarters of its peers. That is a demanding standard in a category where established, decades-old titles compete for the same citations.

Understanding why these metrics matter requires a look at how scientific visibility actually works. Researchers cannot read everything; the volume of pharmaceutical literature published each year runs to hundreds of thousands of articles. Search engines, recommendation tools, and citation databases act as filters, and journals that are indexed in the major databases are dramatically more likely to appear in those filters. An article that is not indexed is, for practical purposes, invisible to much of the global research community, no matter how rigorous its methods or how important its findings. Indexing in SciSearch therefore functions as a guarantee of discoverability, ensuring that the pharmaceutical research published in the journal can be found by the translational scientists, formulation chemists, regulatory affairs professionals, and clinicians who might build on it.

For authors, the practical implications are considerable. Early-career scientists choosing where to submit their work weigh the visibility of a journal heavily, because citations shape careers: grant applications, promotions, and tenure decisions all lean on publication records. A journal with a 5.5 Impact Factor and a Q1 ranking offers a persuasive combination of reach and prestige, particularly for interdisciplinary work in drug delivery, pharmacokinetics, and pharmaceutical technology where the readership spans pharmacy, chemistry, materials science, and medicine. Authors also gain the assurance that their work will be captured in institutional repositories, reported in faculty citation profiles, and counted in national research assessments that draw on Web of Science data.

For readers and research institutions, indexing and citation metrics serve a different but equally important function: they act as quality signals in an environment of information overload. Libraries use indexing status and citation performance to make subscription decisions, allocating finite budgets toward journals that their communities actually use and cite. Systematic reviewers and meta-analysts, whose syntheses of the literature inform clinical guidelines and regulatory decisions, depend on indexed databases to ensure their searches are comprehensive. When a journal is reliably indexed, reviewers can trust that its content will be captured in their search strategies, reducing the risk that important evidence is overlooked. In pharmaceutical research, where a missed finding can influence drug development decisions with billions of dollars and patient safety at stake, that reliability carries real weight.

The journal’s trajectory also illustrates broader dynamics in scholarly publishing. Impact Factors are recalculated annually and can shift with changes in a field’s citation culture, the timing of highly cited articles, and the growth of a journal’s readership. A journal that earns a strong Impact Factor often enters a virtuous cycle: greater visibility attracts stronger submissions, stronger submissions attract more citations, and more citations reinforce the metrics that drew authors in the first place. Entering the Science Citation Index Expanded in 2021 gave the Journal of Pharmaceutical Investigation access to exactly this cycle, and the 2022 figure of 5.5 provides early evidence that the cycle is turning favorably. Sustaining that position will depend on continued editorial rigor, timely publication, and the ability to anticipate where pharmaceutical science is heading next.

Pharmaceutical investigation itself is a field in the midst of remarkable ferment, and the research indexed under this journal’s banner reflects that energy. Drug delivery science is being reshaped by lipid nanoparticles, antibody-drug conjugates, and mRNA platforms whose importance the pandemic made unmistakable. Pharmacokinetic modeling increasingly incorporates artificial intelligence and physiologically based simulation to predict human outcomes from preclinical data. Formulation scientists are tackling biologics, cell therapies, and nucleic acid medicines that defy the traditional tools of the discipline. A Q1-ranked journal embedded in this landscape functions as a convergence point, drawing together the pharmacists, chemical engineers, clinicians, and data scientists whose combined work determines whether laboratory discoveries become medicines on pharmacy shelves.

As the Journal of Pharmaceutical Investigation continues its indexed run, its citation record will be watched not only by its editors and authors but by the wider community that relies on bibliometric indicators to navigate an expanding literature. The 2022 Impact Factor of 5.5 and the Q1 rank of 48 out of 278 in Pharmacology and Pharmacy establish a clear benchmark, and they assure researchers that work published in the journal will be counted, cited, and seen. In a scientific ecosystem where discoverability can determine whether a finding shapes a new therapy or fades unread, the combination of rigorous peer review, inclusion in the Science Citation Index Expanded, and strong citation performance represents the difference between publishing and truly communicating. For pharmaceutical science, one of the most consequential research endeavors of the age, that distinction matters.

Subject of Research: Abstracting, indexing, and citation performance of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, impact factor, Science Citation Index Expanded, SciSearch, Web of Science, pharmacology, pharmacy, Q1 journal, citation metrics, drug delivery, scholarly publishing, pharmaceutical sciences

To understand why this matters, it helps to unpack what indexing in the Science Citation Index Expanded actually means. The Science Citation Index Expanded is one of the core citation databases maintained within the Web of Science, the citation ecosystem originally built on Eugene Garfield’s pioneering work at the Institute for Scientific Information. Inclusion is not automatic. Journals seeking coverage undergo a rigorous evaluation process in which publishers submit documentation of editorial standards, peer review practices, editorial board composition, publication ethics policies, and the international diversity of authorship. Clarivate’s editorial development team assesses whether the journal meets the quality thresholds for foundational coverage and whether its citation performance justifies admission. Being accepted into SciSearch in 2021 signaled that the Journal of Pharmaceutical Investigation had cleared one of the most demanding quality gates in scholarly publishing, a gate that thousands of journals worldwide never pass.

Indexing, in turn, is the precondition for the metric that has become the lingua franca of journal evaluation: the Impact Factor. Calculated annually by Clarivate from the Journal Citation Reports, the Impact Factor for a given year counts the number of citations received in that year by items published in the journal during the two preceding years, divided by the number of citable items published in those same two years. A value of 5.5 for 2022 therefore means that, on average, each citable article published in the journal during 2020 and 2021 was cited 5.5 times in 2022. Because the journal entered SciSearch in 2021, this figure reflects a relatively early citation window, which makes the performance even more striking. New entrants to the citation index typically take several years to accumulate visibility, so a first-quartile placement so soon after admission suggests an unusually rapid adoption by the research community.

The quartile classification adds another layer of meaning. Clarivate assigns journals to categories, and within each category journals are ranked by their Impact Factor and divided into quartiles, with Q1 representing the top 25 percent of titles. The Pharmacology and Pharmacy category is one of the largest and most competitive in the entire Web of Science taxonomy, encompassing 278 journals that range from mega-journals of translational medicine to highly specialized publications in toxicology, drug metabolism, and clinical pharmacy. Ranking 48th in that field places the Journal of Pharmaceutical Investigation firmly within the upper tier of pharmacological publishing, alongside far more established titles with decades of citation history. For authors weighing where to submit manuscripts, quartile placement often carries practical consequences, because funding agencies, promotion committees, and doctoral programs in many countries explicitly require publication in Q1 journals.

The journal’s subject scope helps explain its rising citation profile. Pharmaceutical investigation as a discipline sits at the crossroads of pharmaceutics, biopharmaceutics, drug delivery, pharmacokinetics, and formulation science, and it increasingly absorbs techniques from nanotechnology, materials science, and computational modeling. Research published under this umbrella includes studies of controlled-release systems, lipid-based carriers, polymeric nanoparticles, dissolution testing, bioavailability enhancement, and the physicochemical characterization of novel dosage forms. In recent years the field has been swept up in broader currents reshaping the pharmaceutical sciences, including the explosion of interest in mRNA delivery platforms, the refinement of long-acting injectable formulations, and the application of machine learning to formulation optimization. Journals positioned at the center of these currents tend to attract high citations, because their articles serve as methodological references for large and fast-moving research communities.

The journal in question is published by Springer, one of the major international scientific publishers, and the pharmaceutical sciences have long been a strategic area for the company’s portfolio. The relationship between publisher and index provider is central to the economics of modern scholarly communication. Publishers invest in editorial infrastructure, peer review management, digital preservation, and dissemination platforms, while citation index providers aggregate the resulting literature into evaluative frameworks that institutions use to allocate resources. The feedback loop can be powerful. Indexing increases discoverability through Web of Science searches, discoverability drives downloads and citations, and citations raise the Impact Factor, which in turn attracts stronger submissions from researchers seeking maximum visibility for their work. The journal’s 2022 numbers suggest that this flywheel has begun to turn decisively.

It is worth pausing on how rapidly scholarly metrics themselves have evolved, because the Impact Factor, despite its ubiquity, is a blunt instrument. Critics have long noted that the two-year citation window disadvantages slow-moving fields, that citation distributions within journals are heavily skewed so that a small fraction of papers accounts for most citations, and that aggregate scores can be gamed through editorial strategies such as publishing review articles, which attract citations at a higher rate than primary research. The San Francisco Declaration on Research Assessment, signed by thousands of journals and institutions, urges evaluators to look past journal-level metrics to the actual content and quality of individual papers. Yet the practical reality in much of the world, particularly in Asia, Europe, and Latin America, is that Impact Factors and quartiles remain embedded in grant applications, hiring decisions, and national research assessment exercises. Against that backdrop, a journal’s climb into Q1 translates directly into the career incentives of working scientists.

The pharmaceutical sciences occupy a distinctive position in this evaluative landscape because the field straddles academia and industry. Research on drug delivery and formulation frequently progresses from laboratory bench to clinical application, and the intellectual property and commercial stakes involved mean that citation patterns differ from those in purely academic disciplines. Industry scientists read and cite the pharmaceutical technology literature when designing development programs, and regulatory science considerations, such as bioequivalence standards and dissolution specifications, generate steady citation demand for foundational methodology papers. A Q1 journal in this space therefore functions not only as an academic outlet but as a shared reference point connecting university labs, contract research organizations, generic drug manufacturers, and innovator pharmaceutical companies across dozens of countries.

The timeline of the journal’s ascent is also instructive for understanding how new journals break through in a crowded market. Acceptance into SciSearch in 2021 followed the standard probationary logic of the Web of Science: emerging journals receive partial coverage initially, typically tracking newly published content, and their citation records build as indexed material accumulates. Within a single full cycle the journal achieved an Impact Factor of 5.5 and a category rank of 48 of 278, performance that many long-established titles would consider strong. This acceleration is characteristic of the current era, in which digital distribution, social media amplification, and global submission pipelines allow a well-edited journal to reach its audience far faster than was possible in the print-dominated decades when citation reputations took a generation to form.

For observers of scientific publishing, the broader lesson is that the map of influential journals is not fixed. The Pharmacology and Pharmacy category continues to expand, the tools for evaluating research continue to evolve, and the competition for high-quality manuscripts intensifies as publishers launch new open-access titles and established journals adjust their strategies. The Journal of Pharmaceutical Investigation’s 2022 standing, with an Impact Factor of 5.5 and a first-quartile ranking among 278 pharmacology journals, demonstrates how indexing prestige, editorial focus, and community engagement combine to reshape that map. Whether the journal can sustain and improve its position in future Journal Citation Reports will depend on the same factors that drive all scholarly success: the quality and novelty of the science it publishes, the rigor of its peer review, and its ability to serve as an indispensable resource for the researchers advancing drug development worldwide.

Subject of Research: Indexing and citation performance of the Journal of Pharmaceutical Investigation in the Web of Science Pharmacology and Pharmacy category

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Impact Factor, Science Citation Index Expanded, Web of Science, pharmacology, pharmacy, quartile ranking, citation metrics, drug delivery, pharmaceutical sciences, Springer, Q1 journal

Abstracting and indexing is the infrastructure that makes scientific literature discoverable. When a journal is indexed in a database such as Science Citation Index Expanded, its articles are cataloged with standardized metadata, including author names, affiliations, abstracts, keywords, and cited references. This allows search engines and bibliographic databases to retrieve the work reliably when researchers query the literature. Without such indexing, even high-quality research risks becoming effectively invisible, buried in a journal that major discovery platforms do not cover. The Science Citation Index Expanded, maintained by Clarivate as part of the Web of Science Core Collection, is one of the most selective and widely used indexes in science, and inclusion in it signals that a journal has passed editorial and quality evaluations covering publishing standards, international diversity, peer-review rigor, and citation impact.

The 2022 Impact Factor of 5.5 reflects how often articles published in the journal during 2020 and 2021 were cited in 2022, averaged across the number of substantive items published in that window. Impact Factors are calculated annually from the citation data underlying the Journal Citation Reports, and they remain the single most quoted metric in journal evaluation despite ongoing debate about their limitations. A score of 5.5 places the Journal of Pharmaceutical Investigation comfortably above the median for pharmacology journals, a field that spans basic drug discovery, formulation science, pharmacokinetics, clinical pharmacology, and regulatory science. The Q1 designation, meaning the top quartile of the category, is a threshold that many institutions use when assessing whether a publication outlet meets quality expectations for faculty evaluation, grant reporting, and doctoral training requirements.

The journal’s rise through the rankings has been relatively rapid. Its inclusion in Science Citation Index Expanded dates to 2021, meaning that within roughly two years of entering the index it climbed into the upper quarter of a competitive category containing 278 journals. Pharmacology and Pharmacy is one of the most heavily populated categories in the Journal Citation Reports, encompassing everything from specialist translational titles to large general pharmacology journals, so a rank of 48 out of 278 represents a meaningful position rather than a marginal one. Analysts of scholarly publishing note that newly indexed journals often experience a citation lag, because articles published before indexing are not captured in Impact Factor calculations and it takes time for the journal to accumulate visibility in databases that researchers consult daily. Beating that lag and reaching Q1 quickly suggests strong citation performance for the recently published work that the metric does capture.

For the pharmaceutical research community, the journal’s visibility matters in practical terms. The Journal of Pharmaceutical Investigation publishes work on drug delivery systems, pharmacokinetics and pharmacodynamics, novel formulations, nanomedicine approaches, and investigative studies bridging laboratory findings and clinical application. Researchers in these areas compete for attention in a literature that grows by hundreds of thousands of articles each year. Indexing in SciSearch ensures that their papers appear in Web of Science searches, are linked through citation networks to related work, and are counted in the bibliometric profiles that individual scientists build over their careers. Citation counts drawn from indexed databases feed into h-index calculations, institutional rankings, and the evaluation criteria of major funding agencies, so the difference between an indexed and a non-indexed journal can directly affect a researcher’s professional trajectory.

The broader context is a scholarly publishing industry undergoing rapid change. Open access models, preprint servers, and alternative metrics have diversified how research is disseminated and assessed, yet established indexes such as Science Citation Index Expanded continue to function as gatekeepers of legitimacy. Clarivate applies a multi-stage evaluation to candidate journals, examining editorial consistency, peer-review integrity, the international composition of authorship and editorial boards, citation behavior, and adherence to publishing ethics standards. Journals that fail to meet these criteria are excluded, and those already indexed face periodic re-evaluation, with titles that decline in quality or engage in citation manipulation subject to delisting. In this environment, the Journal of Pharmaceutical Investigation’s sustained inclusion and its Q1 performance indicate that its editorial processes and citation record have withstood scrutiny from the field’s most influential bibliometric authority.

Librarians and research administrators pay close attention to these indicators when making collection and policy decisions. University libraries with constrained budgets rely on indexing status and quartile rankings to decide which subscriptions to maintain, while research offices frequently maintain lists of approved outlets for publication based on Journal Citation Reports quartiles. A Q1 pharmacology journal with a 5.5 Impact Factor is likely to appear on such lists, channeling submissions toward it and reinforcing the citation cycle that sustains its metrics. Critics of this feedback loop argue that it concentrates attention on already prominent journals and can disadvantage regional or emerging titles, but the practical reality for authors is that indexing and quartile remain decisive factors in where they send their manuscripts, particularly in applied fields where industry and regulatory audiences consult the indexed literature.

The journal’s metrics also carry weight internationally, particularly in Asia, where pharmaceutical sciences research output has expanded dramatically over the past two decades. The Journal of Pharmaceutical Investigation has historically served as a venue for research from pharmacology and pharmaceutics communities across Asia and beyond, and its strengthened bibliometric profile gives authors in these regions a high-visibility home for work that might otherwise migrate to Western-centric titles. Bibliometric studies have documented the growing share of global pharmaceutical research produced in countries such as South Korea, Japan, China, and India, and journals that combine regional roots with international indexing standards are well positioned to capture this expanding output. The 2022 figures suggest that the journal is successfully converting that growth into citation impact recognized at a global level.

Looking ahead, the journal’s trajectory will depend on maintaining the editorial quality and citation performance that underpin its current standing. Impact Factors fluctuate from year to year, and a single weak publication cycle can shift a journal’s quartile position in a category as densely packed as Pharmacology and Pharmacy. At the same time, the ongoing evolution of research assessment, including movements such as the Declaration on Research Assessment that encourage evaluation beyond a single metric, may gradually change how much weight the Impact Factor carries. For now, however, the combination of Science Citation Index Expanded coverage, a 5.5 Impact Factor, and a Q1 ranking gives the Journal of Pharmaceutical Investigation a strong position in the competitive market for pharmaceutical sciences research, and a clear signal to authors and readers about the visibility their work can expect to achieve.

Subject of Research: Abstracting and indexing status and citation impact of the Journal of Pharmaceutical Investigation

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, Journal Citation Reports, pharmacology, pharmacy, Q1 journal, Springer, bibliometrics, scholarly publishing

Abstracting and indexing may sound like a dry administrative exercise, but for working scientists it is the infrastructure that determines whether their work is ever seen. When a journal is indexed in a major citation database, every published article gains a standardized record: a structured abstract, author affiliations, subject headings, bibliographic metadata and, critically, a persistent link that other researchers can follow from a search result to the full text. Without that record, even excellent research risks becoming invisible, buried in a journal that search engines and literature reviews rarely surface. Indexing is therefore the mechanism by which a journal’s content enters the bloodstream of scientific communication.

Science Citation Index Expanded, maintained within the Web of Science ecosystem, is one of the most selective and widely recognized of these databases. Journals admitted to the index undergo evaluation of their editorial rigor, publishing standards, peer-review processes, international authorship and citation behavior. Inclusion since 2021 means that all content published by the Journal of Pharmaceutical Investigation from that point onward is systematically captured, allowing citation links to accumulate year by year. This is a prerequisite for any journal that hopes to receive a Journal Impact Factor, the most discussed single number in scholarly publishing.

The Journal Impact Factor itself is a deceptively simple calculation. In any given year, it counts the citations received in that year by items a journal published in the two preceding years, divided by the number of substantive, citable items, chiefly research articles and reviews, published in those same two years. A 2022 impact factor of 5.5 therefore reflects citations earned during 2022 by material published in 2020 and 2021. That figure indicates that, on average, each citable article from those years was cited more than five times within the measurement window, a level of citation intensity that places the journal firmly among the most influential publications in its discipline.

Just as significant as the raw score is the category ranking: 48th out of 278 journals in Pharmacology and Pharmacy. Citation density varies enormously between fields, so a raw impact factor means little until it is contextualized within a discipline. Quartile placement provides that context. A first-quartile position, corresponding to the top 25 percent of journals in the category, signals to authors, reviewers, librarians and funding bodies that the journal sits within the leading tier of venues for pharmaceutical research. It is this rank, rather than the number alone, that most often determines where researchers choose to submit their best work.

For pharmaceutical scientists, the practical consequences are concrete. A Q1 journal with a 5.5 impact factor becomes a preferred destination for studies on novel drug delivery systems, pharmacokinetics, formulation science, nanotechnology-based therapeutics and clinical investigation of new compounds. Authors gain the assurance that their papers will be read by a broad, international audience and that citations will be tracked and attributed correctly. Readers gain the assurance that the journal’s editorial standards have been vetted by an independent indexing body. Institutions, in turn, use these indicators when evaluating faculty productivity, since indexed, highly ranked publications carry more weight in hiring, promotion and grant assessments.

The timing of the indexing also matters. A journal’s early years in a citation index are typically characterized by incomplete citation trails, because it takes time for the database to record references pointing back to newly indexed content. As the 2021 entry point recedes, successive impact factor cycles will draw on an increasingly complete record of the journal’s output. This dynamic often produces a period of citation growth, as previously published articles continue to accrue citations while the denominator of citable items stabilizes. The 2022 figure of 5.5 should therefore be read not as a static endpoint but as a data point in an ongoing trajectory of the journal’s scientific footprint.

It is worth pausing on why metrics like these attract such intense attention, and also on their limits. The Journal Impact Factor was originally designed as a library-management tool, a way to help librarians decide which journals to subscribe to, not as a measure of the quality of any individual paper. A citation to an article can be positive, negative or merely incidental, and citation counts are influenced by article type, review coverage and field trends. Editors and bibliometricians have long cautioned against grading individual researchers by the impact factor of the journals in which they publish. Nevertheless, at the level of the journal as a whole, the metric remains a fast, transparent and universally understood signal of scholarly influence, and quartile rankings in particular continue to shape real decisions across the research enterprise.

Within pharmaceutical science specifically, the value of strong indexing infrastructure is amplified by the field’s translational character. Research published in these pages informs drug formulation, bioavailability enhancement, controlled-release technology, pharmacoeconomics and regulatory science, and its audience spans academic laboratories, industrial research and development groups, clinical pharmacologists and regulatory reviewers. When a study on a novel nanoparticle carrier or an improved oral delivery platform is properly abstracted and indexed, it can be retrieved by a formulator searching for prior art, by a regulatory scientist drafting a dossier or by a clinician weighing a new therapeutic approach. Each of those retrieval events is a potential citation, and each citation strengthens the record on which the journal’s ranking rests. Indexing, citation and scientific progress form a single feedback loop.

The Journal of Pharmaceutical Investigation’s combined achievement, inclusion in Science Citation Index Expanded since 2021, a 2022 Journal Impact Factor of 5.5 and a Q1 ranking of 48 out of 278 in Pharmacology and Pharmacy, therefore represents more than a publishing success. It reflects the cumulative choices of thousands of authors who selected the journal as the home for their work, the reviewers and editors who upheld its scientific standards, and the researchers worldwide whose citations now register in the databases that measure contemporary science. As the journal’s indexed archive matures, its bibliometric record will continue to evolve, and the pharmaceutical research community will be watching how that trajectory develops in the annual release of citation reports to come.

Beyond the headline numbers, the mechanics of how a journal enters and moves through the citation ecosystem deserve closer attention. Science Citation Index Expanded traces its lineage to the Citation Index for Science created in the 1960s, when bibliographers first demonstrated that references embedded in published papers could be aggregated into a searchable network of scholarly influence. That insight, that citations function as explicit acknowledgments of prior intellectual debt, remains the conceptual foundation of modern bibliometrics, and every impact factor calculated today descends from it.

The distinction between being indexed and being measured is also worth clarifying. Journals admitted to Science Citation Index Expanded receive standardized bibliographic records and become part of the citation network, but the Journal Impact Factor itself is released through a separate annual reporting process that evaluates journals after a period of consistent indexing. This staged progression explains why newly indexed journals often need several annual cycles before their metrics stabilize, and why the 2022 assessment of the Journal of Pharmaceutical Investigation represents an early but meaningful reading of its citation performance rather than a mature one.

For authors deciding where to submit, indexing status interacts with other practical considerations. Pharmaceutical research is a fast-moving field in which preprints, conference proceedings and patent literature all compete for attention, so the assurance that a journal’s records are systematically captured and cross-linked carries real weight. Standardized metadata also enables bibliometric tools to disambiguate authors with similar names, connect related datasets and track the diffusion of a finding across disciplines, functions that become increasingly important as pharmaceutical science grows more interdisciplinary, drawing on chemistry, biology, engineering and clinical medicine simultaneously.

The category in which the journal is ranked deserves note as well. Pharmacology and Pharmacy is a broad and crowded classification that encompasses basic pharmacological research, drug design, clinical therapeutics and pharmacy practice, meaning journals compete for citation attention across quite different audiences. Achieving a position within the top quartile of such a heterogeneous category suggests that the journal’s content resonates beyond a narrow specialty, attracting citations from multiple subfields rather than from a single tightly knit community. Cross-disciplinary citation of this kind is often cited by editors as a sign of durable relevance.

Finally, the broader publishing environment shapes how such metrics should be interpreted. Scholarly communication is undergoing sustained change, with open access models, alternative metrics and funder mandates altering how research is disseminated and discovered. Citation-based measures remain the most established currency of journal evaluation, but they increasingly sit alongside downloads, altmetric attention and policy citations in a fuller picture of impact. Within that evolving landscape, a journal that combines rigorous peer review, international reach and strong indexed performance is well positioned to remain a trusted venue as the standards by which science is assessed continue to develop.

Subject of Research: Abstracting and indexing of pharmaceutical research journals and citation metrics

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: abstracting and indexing, Science Citation Index Expanded, SciSearch, Journal Impact Factor, pharmacology, pharmacy, Q1 journal, citation metrics, Web of Science, pharmaceutical investigation, journal ranking, scholarly publishing